Itraconazole--perspectives for the management of invasive aspergillosis.
Itraconazole has become an important option in the management of invasive aspergillosis. The compound has potent and broad spectrum antifungal activity in vitro against Aspergillus spp. with a species- and strain dependent fungicidal mode of action. In vivo, the antifungal efficacy of itraconazole has been demonstrated in several non-immunocompromised and immunocompromised animal models of disseminated and invasive pulmonary aspergillosis. Itraconazole is available in oral and intravenous formulations, displays non-linear plasma pharmacokinetics, and is usually well tolerated. Non-comparative clinical data of itraconazole for therapy of suspected or proven invasive aspergillosis suggest response rates similar to those of conventional amphotericin B; however, the experience with itraconazole for induction therapy of invasive aspergillosis is limited, particularly in profoundly neutropenic patients. Itraconazole has an important role for consolidation and maintenance therapy of patients with invasive aspergillosis, and novel combination therapies involving itraconazole are currently under intensive preclinical investigation as to their usefulness for primary therapy.
Groll
A H
AH
Infectious Disease Research Program, Center for Bone Marrow Transplantation, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Wilhelms University Medical Center, Muenster, Germany. grollan@mednet.uni-muenster.de
D000818:Animals; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy*; D001230:Aspergillus / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D017964:Itraconazole / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D008826:Microbial Sensitivity Tests; D011817:Rabbits
D000935:Antifungal Agents; D017964:Itraconazole